Login to Your Account

Emisphere Signs Roche To Deal For Eligen Technology

By Karen Pihl-Carey

Friday, November 19, 2004
In its first license agreement for small-molecule compounds, Emisphere Technologies Inc. signed on with F. Hoffmann-La Roche Ltd. to develop oral formulations of approved therapies for bone-related diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription